Probiotics for the Prevention of Antibiotic-Associated Diarrhea
- PMID: 36011108
- PMCID: PMC9408191
- DOI: 10.3390/healthcare10081450
Probiotics for the Prevention of Antibiotic-Associated Diarrhea
Abstract
Several communities have started using probiotic-rich fermented foods as therapeutic options with presumed medicinal powers. We now know the importance of microbiome balance and how probiotics can restore imbalances in the microbiome. Probiotics have been tested for a number of clinical uses such as the prevention of antibiotic-associated diarrhea (AAD), the treatment of various diseases such as H. pylori infection, irritable bowel disease, vaginitis, the prevention of allergies, and necrotizing enterocolitis in newborns. AAD has been the most indicated therapeutic use for probiotics. AAD is a common side effect of antibiotic usage, which affects up to 30% of patients. The hypothesis behind using probiotics for AAD is that they help normalize an unbalanced flora. There are many potential mechanisms by which probiotics support intestinal health such as (i) boosting immunity, (ii) increasing gut barrier integrity, (iii) producing antimicrobial substances, (iv) modulating the gut microbiome, (v) increasing water absorption, and (vi) decreasing opportunistic pathogens. Many randomized-controlled trials including the strain-specific trials that use Lactobacillus and Saccharomyces and meta-analyses have shown the benefits of probiotics in addressing AAD. Although adverse events have been reported for probiotics, these are broadly considered to be a safe and inexpensive preventative treatment option for AAD and other gastrointestinal disorders.
Keywords: antibiotic-associated diarrhea (AAD); microbiome; probiotics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Probiotics for prevention of antibiotic-associated diarrhea.J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S58-63. doi: 10.1097/MCG.0b013e3181618ab7. J Clin Gastroenterol. 2008. PMID: 18542041 Review.
-
Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis.Antibiotics (Basel). 2017 Oct 12;6(4):21. doi: 10.3390/antibiotics6040021. Antibiotics (Basel). 2017. PMID: 29023420 Free PMC article. Review.
-
Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea.Curr Opin Biotechnol. 2020 Feb;61:226-234. doi: 10.1016/j.copbio.2020.01.005. Epub 2020 Feb 19. Curr Opin Biotechnol. 2020. PMID: 32087535 Free PMC article. Review.
-
Probiotics and prebiotics in infants and children.Curr Infect Dis Rep. 2013 Jun;15(3):251-62. doi: 10.1007/s11908-013-0334-4. Curr Infect Dis Rep. 2013. PMID: 23640127
-
Bacteroides fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses.Front Immunol. 2018 May 9;9:1040. doi: 10.3389/fimmu.2018.01040. eCollection 2018. Front Immunol. 2018. PMID: 29868005 Free PMC article.
Cited by
-
Polysaccharides of natural products alleviate antibiotic-associated diarrhea by regulating gut microbiota: a review.Arch Microbiol. 2024 Nov 7;206(12):461. doi: 10.1007/s00203-024-04184-0. Arch Microbiol. 2024. PMID: 39508892 Review.
-
Gut dysbiosis mediates the association between antibiotic exposure and chronic disease.Front Med (Lausanne). 2024 Nov 6;11:1477882. doi: 10.3389/fmed.2024.1477882. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39568738 Free PMC article. Review.
-
The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story.Microorganisms. 2024 Jan 18;12(1):194. doi: 10.3390/microorganisms12010194. Microorganisms. 2024. PMID: 38258020 Free PMC article. Review.
-
Stress-induced changes in cognitive function and intestinal barrier integrity can be ameliorated by venlafaxine and synbiotic supplementations.PeerJ. 2024 Feb 28;12:e17033. doi: 10.7717/peerj.17033. eCollection 2024. PeerJ. 2024. PMID: 38435986 Free PMC article.
-
Probiotics: truths and illusions.Iran J Microbiol. 2024 Feb;16(1):1-3. doi: 10.18502/ijm.v16i1.14865. Iran J Microbiol. 2024. PMID: 38682066 Free PMC article. No abstract available.
References
-
- van den Nieuwboer M., Van De Burgwal L.H., Claassen E. A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle. PharmaNutrition. 2015;4:9–18. doi: 10.1016/j.phanu.2015.09.003. - DOI
Publication types
LinkOut - more resources
Full Text Sources